$97.99
0.40% yesterday
Nasdaq, Feb 04, 10:04 pm CET
ISIN
US3755581036
Symbol
GILD
Sector
Industry

Gilead Sciences Stock price

$97.99
+6.76 7.41% 1M
+23.16 30.95% 6M
+5.62 6.08% YTD
+21.28 27.74% 1Y
+34.09 53.35% 3Y
+30.59 45.39% 5Y
-0.44 0.45% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
-0.39 0.40%
ISIN
US3755581036
Symbol
GILD
Sector
Industry

Key metrics

Market capitalization $122.12b
Enterprise Value $138.59b
P/E (TTM) P/E ratio 1,104.74
EV/FCF (TTM) EV/FCF 14.70
EV/Sales (TTM) EV/Sales 4.90
P/S ratio (TTM) P/S ratio 4.32
P/B ratio (TTM) P/B ratio 6.61
Dividend yield 3.14%
Last dividend (FY24) $3.08
Revenue growth (TTM) Revenue growth 3.72%
Revenue (TTM) Revenue $28.27b
EBIT (operating result TTM) EBIT $10.59b
Free Cash Flow (TTM) Free Cash Flow $9.43b
Cash position $6.70b
EPS (TTM) EPS $0.09
P/E forward 507.05
P/S forward 4.31
EV/Sales forward 4.89
Short interest 2.02%
Show more

Create a Free Account to create an Gilead Sciences alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Gilead Sciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

33 Analysts have issued a Gilead Sciences forecast:

18x Buy
55%
15x Hold
45%

Analyst Opinions

33 Analysts have issued a Gilead Sciences forecast:

Buy
55%
Hold
45%

Financial data from Gilead Sciences

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
28,273 28,273
4% 4%
100%
- Direct Costs 6,230 6,230
16% 16%
22%
22,043 22,043
1% 1%
78%
- Selling and Administrative Expenses 2,976 2,976
25% 25%
11%
- Research and Development Expense 5,718 5,718
2% 2%
20%
13,349 13,349
11% 11%
47%
- Depreciation and Amortization 2,762 2,762
9% 9%
10%
EBIT (Operating Income) EBIT 10,587 10,587
11% 11%
37%
Net Profit 126 126
98% 98%
0%

In millions USD.

Don't miss a Thing! We will send you all news about Gilead Sciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Gilead Sciences Stock News

Positive
Seeking Alpha
one day ago
Company sees strong growth in VEKLURY sales, driven by increased Covid-19 hospitalizations, with Q3 2024 sales up 9% to $692 million. LIVDELZI shows promise for long-term growth, with FDA Accelerated Approval for PBC and potential EMA approval in Q1 2025. TRODELVY sales increased by 17% year-over-year, with potential expansion into ES-SCLC and other Trop-2 expressing solid tumors.
Positive
Market Watch
one day ago
Trump has pledged to protect Social Security and Medicare throughout his campaign, one analyst noted, but this was the first time he added Medicaid to the list.
Neutral
PRNewsWire
6 days ago
Cognizant will provide AI-driven solutions to enhance customer service, employee engagement, and business value TEANECK, N.J. , Jan. 30, 2025 /PRNewswire/ -- Cognizant (NASDAQ: CTSH) has announced an expansion of its longstanding relationship with biopharmaceutical leader Gilead Sciences (NASDAQ: GILD) that aims to unlock even greater value for Gilead as it advances innovations to prevent and t...
More Gilead Sciences News

Company Profile

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firms primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster, CA.

Head office United States
CEO Daniel O'Day
Employees 18,000
Founded 1987
Website www.gilead.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today